A Lockhart

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi request reprint The peripheral benzodiazepine receptor ligand PK11195 binds with high affinity to the acute phase reactant alpha1-acid glycoprotein: implications for the use of the ligand as a CNS inflammatory marker
    Andrew Lockhart
    GlaxoSmithKline, Translational Medicine and Technology, Addenbrooke s Centre for Clinical Investigation, Addenbrooke s Hospital, Cambridge CB2 2GG, UK
    Nucl Med Biol 30:199-206. 2003
  2. pmc In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain
    Liang Ye
    GlaxoSmithKline, Clinical Science and Technology, Neurology DM, New Frontiers Science Park, Harlow, UK
    J Neurochem 105:1428-37. 2008
  3. ncbi request reprint Imaging Alzheimer's disease pathology: one target, many ligands
    Andrew Lockhart
    GlaxoSmithKline, Addenbrooke s Centre for Clinical Investigation ACCI, Box No 128, Addenbrookes Hospital, Hills Road, Cambridge CB2 2GG, UK
    Drug Discov Today 11:1093-9. 2006
  4. ncbi request reprint PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis
    A Lockhart
    GlaxoSmithKline, Clinical Science and Technology, CPDM and NGI CEDD, NFSP North, Third Avenue, Harlow, Essex, CM19 5AW, UK
    Brain 130:2607-15. 2007
  5. ncbi request reprint Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils
    Andrew Lockhart
    Translational Medicine and Technology, GlaxoSmithKline Research and Development, Addenbrookes Hospital, Cambridge CB2 2GG, United Kingdom
    J Biol Chem 280:7677-84. 2005
  6. ncbi request reprint Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrils
    Liang Ye
    Translational Medicine and Genetics, GlaxoSmithKline Research and Development, Addenbrookes Hospital, Cambridge, CB2 2GG, United Kingdom
    J Biol Chem 280:23599-604. 2005
  7. ncbi request reprint Characterisation of the binding of amyloid imaging tracers to rodent Abeta fibrils and rodent-human Abeta co-polymers
    Liang Ye
    GlaxoSmithKline Research and Development, Translational Medicine and Genetics, Addenbrookes Hospital, Cambridge, UK
    Biochem Biophys Res Commun 347:669-77. 2006
  8. ncbi request reprint PPARgamma activation enhances cell surface ENaCalpha via up-regulation of SGK1 in human collecting duct cells
    Guizhu Hong
    Translational Medicine and Technology, GlaxoSmithKline, ACCI, Addenbrooke s Hospital, Hills Road, Cambridge, CB2 2GG, UK
    FASEB J 17:1966-8. 2003
  9. doi request reprint Monitoring the amyloid beta-peptide in vivo--caveat emptor
    Paul W Thompson
    GlaxoSmithKline, R and D China, UK Hub, Cambridge, UK
    Drug Discov Today 14:241-51. 2009
  10. pmc Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies
    Paul W Thompson
    GlaxoSmithKline, R and D China, UK Hub, Addenbrookes Hospital, Cambridge, UK
    J Neurochem 109:623-30. 2009

Detail Information

Publications10

  1. ncbi request reprint The peripheral benzodiazepine receptor ligand PK11195 binds with high affinity to the acute phase reactant alpha1-acid glycoprotein: implications for the use of the ligand as a CNS inflammatory marker
    Andrew Lockhart
    GlaxoSmithKline, Translational Medicine and Technology, Addenbrooke s Centre for Clinical Investigation, Addenbrooke s Hospital, Cambridge CB2 2GG, UK
    Nucl Med Biol 30:199-206. 2003
    ..Finally, local synthesis of AGP at the site of brain injury may contribute the pattern of [(11)C]PK11195 binding observed in neuroinflammatory diseases...
  2. pmc In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain
    Liang Ye
    GlaxoSmithKline, Clinical Science and Technology, Neurology DM, New Frontiers Science Park, Harlow, UK
    J Neurochem 105:1428-37. 2008
    ..Lewy bodies pathology is therefore unlikely to contribute significantly to the retention of PIB in positron emission tomography imaging studies...
  3. ncbi request reprint Imaging Alzheimer's disease pathology: one target, many ligands
    Andrew Lockhart
    GlaxoSmithKline, Addenbrooke s Centre for Clinical Investigation ACCI, Box No 128, Addenbrookes Hospital, Hills Road, Cambridge CB2 2GG, UK
    Drug Discov Today 11:1093-9. 2006
    ....
  4. ncbi request reprint PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis
    A Lockhart
    GlaxoSmithKline, Clinical Science and Technology, CPDM and NGI CEDD, NFSP North, Third Avenue, Harlow, Essex, CM19 5AW, UK
    Brain 130:2607-15. 2007
    ....
  5. ncbi request reprint Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils
    Andrew Lockhart
    Translational Medicine and Technology, GlaxoSmithKline Research and Development, Addenbrookes Hospital, Cambridge CB2 2GG, United Kingdom
    J Biol Chem 280:7677-84. 2005
    ..The presence of additional ligand-binding sites presents potential new targets for ligand development and may allow a more complete modeling of the current positron emission tomography data...
  6. ncbi request reprint Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrils
    Liang Ye
    Translational Medicine and Genetics, GlaxoSmithKline Research and Development, Addenbrookes Hospital, Cambridge, CB2 2GG, United Kingdom
    J Biol Chem 280:23599-604. 2005
    ....
  7. ncbi request reprint Characterisation of the binding of amyloid imaging tracers to rodent Abeta fibrils and rodent-human Abeta co-polymers
    Liang Ye
    GlaxoSmithKline Research and Development, Translational Medicine and Genetics, Addenbrookes Hospital, Cambridge, UK
    Biochem Biophys Res Commun 347:669-77. 2006
    ....
  8. ncbi request reprint PPARgamma activation enhances cell surface ENaCalpha via up-regulation of SGK1 in human collecting duct cells
    Guizhu Hong
    Translational Medicine and Technology, GlaxoSmithKline, ACCI, Addenbrooke s Hospital, Hills Road, Cambridge, CB2 2GG, UK
    FASEB J 17:1966-8. 2003
    ..This pathway may play a role in sodium retention caused by activation of PPARgamma in man...
  9. doi request reprint Monitoring the amyloid beta-peptide in vivo--caveat emptor
    Paul W Thompson
    GlaxoSmithKline, R and D China, UK Hub, Cambridge, UK
    Drug Discov Today 14:241-51. 2009
    ..Additional candidate biofluid (tau and isoprostanes) and imaging (MRI, FDG-PET) measures may provide alternative supporting evidence of drug activity and subsequent clinical efficacy in patient populations...
  10. pmc Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies
    Paul W Thompson
    GlaxoSmithKline, R and D China, UK Hub, Addenbrookes Hospital, Cambridge, UK
    J Neurochem 109:623-30. 2009
    ....